Cumberland Pharmaceuticals (CPIX) Interest & Investment Income (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Interest & Investment Income of $78031.0 for Q1 2026, down 15.15% sequentially from $91967.0 in Q4 2025, and down 37.93% YoY from $125709.0 in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Interest & Investment Income (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Interest & Investment Income for 17 years, with the latest figure at $78031.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 37.93% year-over-year to $78031.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $429070.0 (up 18.07% YoY) and the FY2025 annual result came in at $476748.0, up 42.55% from the prior year.
- Interest & Investment Income eased to $78031.0 in Q1 2026 per CPIX's latest filing, from $91967.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $131583.0 in Q3 2025 and troughed at $15066.0 in Q2 2022.
- A 5-year average of $74969.5 and a median of $78031.0 in 2026 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2026: Interest & Investment Income jumped 585.1% in 2022, then sank 37.93% in 2026.
- Over 5 years, Interest & Investment Income stood at $45696.0 in 2022, then jumped by 77.26% to $81000.0 in 2023, then soared by 31.69% to $106667.0 in 2024, then retreated by 13.78% to $91967.0 in 2025, then declined by 15.15% to $78031.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $78031.0, $91967.0, and $131583.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Cumberland Pharmaceuticals | 117.61 Mn | 113.74 Mn | - | 60,884.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60,884.00 |
| Mar 31, 2026 | 78,031.00 |
| Dec 31, 2025 | 91,967.00 |
| Sep 30, 2025 | 131,583.00 |
| Jun 30, 2025 | 127,489.00 |
| Mar 31, 2025 | 125,709.00 |
| Dec 31, 2024 | 106,667.00 |
| Sep 30, 2024 | 69,190.00 |
| Jun 30, 2024 | 61,841.00 |
| Mar 31, 2024 | 96,746.00 |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | 98,603.00 |
| Jun 30, 2023 | 57,061.00 |
| Mar 31, 2023 | 50,190.00 |
| Dec 31, 2022 | 45,696.00 |
| Sep 30, 2022 | 21,602.00 |
| Jun 30, 2022 | 15,066.00 |
| Mar 31, 2022 | 16,041.00 |
| Dec 31, 2021 | 6,670.00 |
| Sep 30, 2021 | 7,394.00 |